In their 1968 recording of Revolution #1 the Beatles John Lennon sang, You say you want a revolution, well you know, we all want to change the world. GLP-1s and their successors are well on the road to changing the world, and Svetlana Mojsov, Joel Habener and Lotte Knudsen are recognized today as the revolutionaries who lit the match
A clinical trial by Krger et al
Published online January 27, 2026 DOI: Abstract PDF Supplementary Material Background/Aims Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide
However, these are uncommon and usually identified early in treatment
As approved indications continue to broaden, and adoption scales in those with established disease, the cumulative impact on public health could be profound
indeed, any augmentation of GLP-1 responses would probably be welcome and could help control glycaemia in patients with type 2 diabetes